Decisions about vaccination for children on dupilumab are complex and depend on both the child’s current treatment and the type of vaccination required.

Pediatric patients with atopic dermatitis on treatment with dupilumab can safely receive inactivated vaccines, whereas live attenuated vaccines, including boosters, should be avoided or carefully considered on an individual basis and with the involvement of appropriate pediatric subspecialists until further evidence demonstrates their safety.